Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05293626 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
A Phase 1 study of Leber Hereditary Optic Neuropathy (LHON), sponsored by Neurophth Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT05293626 is a Phase 1 study of Leber Hereditary Optic Neuropathy (LHON) that is active but no longer recruiting, run by Neurophth Therapeutics. The registered enrollment target is 12 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT05293626, a Phase 1 study of Leber Hereditary Optic Neuropathy (LHON), is active but no longer recruiting, sponsored by Neurophth Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this clinical study is to evaluate the safety and efficacy of NR082 in the treatment of LHON caused by mitochondrial ND4 gene mutation. This study will enroll subjects aged ≥ 18 years old and ≤ 75 years old to receive a single unilateral intravitreal (IVT) injection of NR082 to evaluate its safety and efficacy. The clinical manifestations of all subjects are to be reduced visual acuity caused by LHON associated with ND4 mutation, with laboratory test showing G11778A mutation (a CLIA-certified laboratory) and reduced visual acuity lasted for \> 6 months and \< 10 years.
Conditions Studied
Interventions
- DRUG NR082 Injection
- DEVICE Injection needle
Study Locations (3)
California
- Stanford Byers Eye Institute - Palo Alto
Colorado
- University of Colorado Health Eye Center - Aurora
Pennsylvania
- Wills Eye Hospital, Neuro Ophthalmology Department - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05293626
The ClinicalTrials.gov registry entry for NCT05293626 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurophth Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leber Hereditary Optic Neuropathy (LHON) appearing as the primary indexed condition, and to 2 interventions - of which NR082 Injection is the first listed.
NCT05293626 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05293626 about?
NCT05293626 is a clinical study titled "Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations". The objective of this clinical study is to evaluate the safety and efficacy of NR082 in the treatment of LHON caused by mitochondrial ND4 gene mutation. This study will enroll subjects aged ≥ 18 years old and ≤ 75 years old to receive a single unilateral intravitreal (IVT) injection of NR082 to eval...
What is the current status of trial NCT05293626?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-05-22. Estimated completion is 2029-12.
What conditions does trial NCT05293626 study?
This clinical trial studies the following conditions: Leber Hereditary Optic Neuropathy (LHON).
What interventions are being tested in trial NCT05293626?
The interventions under investigation include: NR082 Injection (DRUG), Injection needle (DEVICE).
Who is sponsoring clinical trial NCT05293626?
This trial is sponsored by Neurophth Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05293626 being conducted?
This trial has 3 study locations across California, Colorado, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.